A Leading Oncology Player

Developing Proenzyme Therapy to Treat and Prevent Metastatic Cancer

Propanc Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. Together with our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Our leading products are variations upon our novel formulation and involve or employ proenzymes, which are inactive precursors of enzymes.

View Company PDF

Developing Proenzyme Therapy to Treat and Prevent Metastatic Cancer

Latest Developments

Propanc commences investigational medicinal product manufacture of PRP for First-In-Human studies

Propanc successfully completes GLP-compliant 28-day repeat-dose toxicity study for PRP

Positioning ourselves for worldwide regulatory approval

Progressing development

The progressing development of a once-daily proteolytic proenzyme cancer treatment through non-clinical and clinical development, and ultimately, obtaining regulatory approval as an effective, clinically proven therapeutic option.

Multiple mechanisms of action

Unlike many products approved for the treatment of cancer, our treatment exerts multiple effects on cancerous cells, which inhibits tumor growth and potentially stops it from spreading throughout the body.

Encouraging data from patient treatment

Scientific research undertaken over the last 15 years and the clinical experience from treating patients in the UK and Australia has provided evidence that PRP may be an effective treatment against cancer, and warrants further development.

Unique intellectual property

We are focusing on building a significant portfolio of intellectual property around our scientific understanding of the effects of proteolytic proenzyme in cancer, identifying new formulations, new routes of administration and potential new therapeutic targets.

Increasing Demand for Easy-to-Administer Cancer Treatments

Cancer is the leading cause of death worldwide, accounting for 7.6 million deaths (around 13% of all deaths) in 2008.*

*Source: http://www.who.int/mediacentre/factsheets/fs297/en/
Supplying a Market Need

Technology Based on Pancreatic Enzyme Therapy

Pancreatic Enzyme Therapy uses natural elements within our organism that could help us treat cancer. We are developing a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis, the main cause of patient death from cancer.

How Our Technology Works
Play Video

A New Frontier In Cancer Therapy

Watch how Propanc is pioneering a new approach to cancer therapy

Halting Cancer Cells’ Ability to Invade and Metastasize

We are developing a therapeutic solution for the treatment of patients with advanced stages of cancer targeting solid tumors. Our therapy has anti-cancer effects that block tumor growth and its aggressive dissemination.

View Our Product Pipeline

The Propanc Difference

Instead of targeting tumor cell death, we focus on inducing cell differentiation. We convince malignant cells to stop proliferating and encourage them to continue their work as a specific cell type.

What Makes Us Different

An International R&D Network that’s Driven to Excellence

Our strong partnerships are helping to advance and perfect our technology and candidates.

The Andalusian Public Foundation for biomedical research in eastern Andalusia, Alejandro Otero-FIBAO is a non-profit foundation specializing in the comprehensive management of biomedical research.

We have a Joint IP Ownership and Commercialization Agreement with Bath University.

Our ongoing joint research collaboration with the University of Grenada and Universidad de Jaen involved investigating the effects of PRP on cancer cells, identifying molecular target identification and new compound screenings.

With the help of vivoPharm, we are conducting animal testing on PRP to determine its safety and efficacy, as well as determining metabolic effects prior to conducting human studies.

We have partnered with Q Biologicals to undertake the GMP-compliant investigational medicinal product (IMP) manufacture of PRP for human use.

Our ongoing joint research collaboration with The ibs.GRANADA involves studying the in-vivo effect of the anti-tumoral formulation of PRP against cancer stem cells.

Unique Intellectual Property

We are building an IP portfolio around our scientific understanding of the effects of proenzymes in cancer, identifying new formulations, new routes of administration and potential new therapeutic targets.

Ownership

  • A Joint Commercialization Agreement with Bath University
  • Bath University has assigned patents to us in exchange for rights for research use plus 2% royalties

Patent Details

  • We have filed six patent applications relating to our lead product, PRP.
  • The first international patent filed in October 2010 refers to a pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent*
    *Selected from a selenium compound, a vanilloid compound, and a cytoplasmic glycolysis reduction agent.
  • In 2016 and 2017 we filed five other patent applications, where two were filed in Spain and one was filed in the United States. Two others were filed under the Patent Cooperation Treaty, or PCT, where applicants can seek protection for an invention in over 150 countries, simultaneously.

Prior Art

  • A U.S. patent, Trnka et al, Pharmaceutical composition containing an isolated protease proenzyme, amylase & aprotinin was filed in January, 1999
  • Novak & Trnka, Proenzyme Therapy of Cancer, Anti-cancer Research was filed in 2005

Current Status

  • Our lead patent has been granted in Australia, Japan, Indonesia, Israel, New Zealand, Singapore and South Africa. In the United States, the application has been allowed by the U.S. Patent and Trademark Office, but has not yet been issued.
  • We have begun entering a national phase in individual countries and regions.
  • We will enter national phase for our latest international patent applications once the initial examinations in their country of origin are completed.